Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT06742515RecruitingPhase 2
Blinatumomab with lower-dose chemo for B-ALL
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
Hangzhou, ZhejiangAges 15–59 - NCT06742073Recruiting
Study of H syndrome and inflammation
This study looks at the link between H syndrome and related health issues, such as inflammation or histiocytosis (a type of immune cell disorder). It helps researchers learn more about how this rare genetic condition affects the body.
Petah TikvaAges Any age - NCT06742528Recruiting
Comparing two iron medicines for children with low iron
This study compares two iron medicines—one a simple iron pill and the other a gentle iron form—to see which works better for children with low iron levels (anemia). If your child has iron deficiency anemia and none of the listed health issues, they may be able to join.
Peshawar, KPKAges 6 months–5 years - NCT06742463RecruitingPhase 2
VHAG for relapsed or refractory T-cell acute leukemia
This trial tests a combination of drugs (venetoclax, homoharringtonine, cytarabine, and g-CSF, called VHAG) for people whose T-cell acute leukemia or lymphoma has come back or hasn't responded to treatment. It aims to see if this combination can help when other treatments haven't worked.
Hangzhou, ZhejiangAges 14–74 - NCT06571552Recruiting
Comparing two blood filtering methods' effect on clotting
This study compares two ways of filtering your blood (plasmapheresis) to see how each affects your blood's ability to clot. If you already receive regular plasmapheresis with citrate, you might help doctors learn which method is safer for you.
NîmesAges 18 years+ - NCT04817462Recruiting
Liver biopsy in people with haemophilia gene therapy
This study takes a small liver tissue sample (a liver biopsy) in men who previously received haemophilia gene therapy. The goal is to learn more about how the gene therapy works and how safe it is for the liver.
LondonAges 18–80 - NCT05967416RecruitingPhase 1
Early-phase lymphoma trial testing a new targeted immune treatment
This Phase 1 study tests SIRPant-M, a new immune-based treatment, in adults with lymphoma that has come back or not responded to earlier care. It may help by shrinking lymphoma using either the drug alone or the drug plus a targeted radiation treatment for certain lymphoma types.
Duarte, CaliforniaAges 18 years+ - NCT07546760RecruitingPhase 1
Study of how liver disease affects two new medications
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
Chandler, ArizonaAges 18–85 - NCT07545603RecruitingPhase 2
XNW5004 tablets for hard-to-treat follicular lymphoma
This study tests a new tablet called XNW5004 in patients with follicular lymphoma (a type of blood cancer) that has come back or stopped responding after multiple prior treatments. The goal is to see if this drug can help control the cancer in patients who have limited options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07549698RecruitingPhase 1/Phase 2
CRISPR Gene Therapy for Immune Blood Disorders
This trial tests CTX112, a new CRISPR gene therapy that modifies your immune cells to treat severe immune thrombocytopenic purpura (ITP) or warm autoimmune hemolytic anemia (WAIHA) that hasn't responded to standard treatments. The goal is to see if it's safe and can help your body stop attacking its own blood cells.
Rochester, MinnesotaAges 18 years+ - NCT07549516Recruiting
Asciminib for chronic myeloid leukemia in germany
This study tests whether the drug asciminib is safe and works well for people with chronic myeloid leukemia, compared to standard TKIs. You may join if you're newly diagnosed or have tried only one previous TKI treatment.
Baden-Baden, Baden-WurttembergAges 18–100 - NCT07545395RecruitingPhase 3
Safety study of KN057 blood clot prevention in hemophilia
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
Tianjin, Tianjin MunicipalityAges 12–65 - NCT06082284Recruiting
M protein detection study for adult patients
This study is looking for adults at Zhujiang Hospital to test a new, highly sensitive method for detecting a protein called M protein in the blood. It helps doctors understand how common this protein is in different patients.
Guangzhou, GuangdongAges 18 years+ - NCT07551037RecruitingPhase 1
Immune Therapy to Prevent AML Relapse After Chemotherapy
This trial tests a new type of maintenance therapy for acute myeloid leukemia (AML) patients who have already responded well to chemotherapy. The treatment uses your own immune cells to help prevent the cancer from coming back.
Fuzhou, FujianAges 18–70 - NCT07545473Recruiting
Eye Imaging to Detect Brain Disease Markers
This study uses a special camera to photograph the back of your eye in detail. Researchers believe changes in the eye may reflect brain diseases like Alzheimer's or Parkinson's, and this imaging could help detect these conditions earlier.
Melbourne, VictoriaAges 30 years+ - NCT07548710RecruitingPhase 2
SA plus X for newly diagnosed AML
This trial tests a combination of two drugs, SA and X, for people who have just been diagnosed with acute myeloid leukemia (AML) and have not yet received treatment (except hydroxyurea to lower white blood cells). The goal is to see if the combination works better than standard care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07548983RecruitingPhase 1
Maintenance therapy after stem cell transplant for AML
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
Portland, OregonAges 18 years+ - NCT07548697RecruitingEarly Phase 1
Safety study of CT1182 for relapsed B-cell lymphoma
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
Wuhan, HubeiAges 18–75 - NCT07547007Recruiting
Exercise Program to Improve Life Quality After Myeloma Treatment
This study tests whether a 6-month personalized exercise program—done partly at home and partly at a center—can improve quality of life for patients with multiple myeloma (a blood cancer) who are receiving ongoing chemotherapy or targeted drugs. The program is tailored to your abilities and fits into your regular hospital visits.
AnnecyAges 61 years+ - NCT07546188Recruiting
AI System to Help Lymphoma Patients Take Oral Medications
This trial tests an artificial intelligence (AI) system designed to predict and help prevent medication non-compliance—meaning skipped or missed doses—in lymphoma patients taking oral (by-mouth) therapies. The goal is to catch problems early and support patients in taking their medications as prescribed.
Charleroi, HainautAges 18 years+ - NCT07549477Recruiting
Heart imaging study for cancer patients with catheter clots
This study uses a special heart imaging test (cardiac MRI) to look for and understand blood clots that may form around central catheters (tubes placed in veins) in people with cancer. The imaging helps doctors see if clots are present and what type they are, which could improve how they care for cancer patients.
Basking Ridge, New JerseyAges 18 years+ - NCT06071871RecruitingPhase 2
A trial of 3 drugs before or after CAR-T for lymphoma
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
LondonAges 18 years+ - NCT02432560Recruiting
Testing sirolimus for long-term treatment of LAM
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
Stanford, CaliforniaAges 18 years+ - NCT06745622RecruitingPhase 2
Long-term safety of HSK39297 for PNH patients
This study is for people with paroxysmal nocturnal hemoglobinuria (PNH) who have already taken the experimental drug HSK39297. It checks the long-term safety of continuing the treatment and makes sure it is still helpful.
Nanjing, JiangsuAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.